2019台灣生技月 Bio Taiwan 生物科技大展

2019 台灣生技月 南港展覽館

講師

Michael Liu Su

Session 6 – Protein Drugs and Combination Products
Date: 25 July (Thursday)  14:00 – 17:30
Venue: 3F, Bldg. A, CTBC Financial Park, Ballroom B
 


 

Michael Liu Su

Associate
Finnegan, Henderson, Farabow, Garrett & Dunner, LLP

 
Michael Liu Su’s practice spans both patent and trade secret matters, involving industries such as biotechnology, pharmaceuticals, chemical, medical devices, automotive, and computer technology. His litigation experience includes representing clients before state and federal court, and before arbitrators. He also maintains an active patent prosecution and due diligence practice.
 
Michael has successfully represented clients in federal district and appellate courts and in arbitration cases. His litigation experience includes pre-suit investigation and counseling, fact and expert discovery, claim construction, motion practice, trial, and appeal. He has also successfully defended patents before the Patent Trial and Appeal Board (PTAB) in inter partes reviews (IPR). Michael has litigated trade secret cases, both under state law and under the federal Defend Trade Secrets Act.
 
Michael also maintains a noncontentious patent practice, including representing clients in freedom-to-operate analyses, providing opinions on patent validity in licensing and acquisition matters, and prosecuting patent applications before U.S. Patent and Trademark Office and, when on appeal, before the PTAB and the U.S. Court of Appeals for the Federal Circuit.
 
Education
University of California, Berkeley, School of Law
J.D., 2014
National Yang-Ming University
M.S., Genome Sciences, 2008
National Yang-Ming University
B.S., Life Science, 2007


Session Speech Title & Synopsis:
Patent Considerations for Protein Drugs and Combination Products
 
Because of their complex nature, protein drugs and combination products face unique patent issues. U.S. attorneys Amanda Murphy and Michael Liu Su, from the intellectual property law firm Finnegan, will discuss key issues and recent legal developments that companies should bear in mind when seeking U.S. patents that are valid and provide sufficient scope of protection. Such issues and developments include patent eligibility, nonobviousness, and the written description and enablement requirements. For example, it is critical that companies know whether their inventions are patentable under the ever-changing legal requirement for patent eligibility, and whether their patents’ disclosures provide sufficient support for the full scope of the patent claims. This presentation will provide helpful guidance for making such determinations.